Tranquis Therapeutics to Present Preclinical Data on TQS-168 at ARDD 2022
-TQS-168 demonstrated robust geroprotective effects in preclinical studies- REDWOOD CITY, Calif.–(BUSINESS WIRE)–Tranquis Therapeutics, Inc., a clinical stage immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases, today announced it will present preclinical data on the anti-aging effects of TQS-168, a small molecule modulator of PGC-1a, at ARDD … [Read more…]
